CA2256013C - Crystal modification of 1-(2,6-difluorobenzyl)-1h-1,2,3-triazole-4-carboxamide and its use as antiepileptic - Google Patents
Crystal modification of 1-(2,6-difluorobenzyl)-1h-1,2,3-triazole-4-carboxamide and its use as antiepileptic Download PDFInfo
- Publication number
- CA2256013C CA2256013C CA002256013A CA2256013A CA2256013C CA 2256013 C CA2256013 C CA 2256013C CA 002256013 A CA002256013 A CA 002256013A CA 2256013 A CA2256013 A CA 2256013A CA 2256013 C CA2256013 C CA 2256013C
- Authority
- CA
- Canada
- Prior art keywords
- ang
- weak
- modification
- medium
- crystal modification
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
- C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D249/04—1,2,3-Triazoles; Hydrogenated 1,2,3-triazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Pain & Pain Management (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
The invention relates to the novel modification A or A' of the compound 1-(2, 6-difluoroben-zyl)-1H-1,2,3-triazole-4-carboxamide of formula (I), its use for the treatment of epilepsy, and pharmaceutical preparations comprising this crystal modification.
Description
2 PCT/EP98/03427 CRYSTAL MODIFICATION OF 1-(2,6-DIFLUOROBENZYL)-1H-1,2,3-TRIAZOLE-4-CARBOXAMIDE
AND ITS USE
AS ANTIEPILEPTIC
Background of the invention The compound 1-(2,6-difluorobenzyl)-1 H-1,2,3-triazole-4-carboxamide of the formula O
N
F NN
&F
is described in the European Patent Application with the Publication No. 0 199 (EP 199262), for example in Example 4. Valuable pharmacological properties are attributed to this compound; thus, it can be used, for example, as an antiepileptic. The compound 1-(2,6-difluorobenzyl)-1 H-1,2,3-triazole-4-carboxamide is obtained according to EP 199262, starting from 2,6-difluorobenzyl azide via the formation of 1-(2,6-difluorobenzyl)-1 H-1,2,3-triazole-4-carboxylic acid, the procedure being analogous to Example 2.
EP 199262 provides no information at all about possible crystal modifications obtained. If the method according to the Example 4 is used in conjunction with Example 2, the crude 1-(2,6-difluorobenzyl)-1 H-1,2,3-triazole-4-carboxamide product obtained is finally crystallized from ethanol. However, EP 199262 gives no indication that such recrystallization is specifically to be applied, or on particular conditions that might be adopted.
It has now surprisingly been found that the different crystal modifications (polymorphism) characterized below can be prepared by choice of specially selected process conditions, for example through the choice of an appropriate solvent for the recrystallization or the duration of the recrystallization.
Description of the invention 1-(2,6-Difluorobenzyl)-1 H-1,2,3-triazole-4-carboxamide can be obtained in the novel crystal modifications A, A', B and C. These crystal modifications differ with respect to their thermodynamic stability, in their physical parameters, such as.the absorption pattern of IR
and Raman spectra, in X-ray structure investigations and in their preparation processes.
The invention relates to the novel crystal modifications A and A', their preparation and use in pharmaceutical preparations comprising this crystal modification.
The modification A', compared with A, has defects in the crystal lattice.
These are detectable, for example, by X-ray analysis; e.g. by smaller line spacings with otherwise predominantly identical lines or bands.
The novel crystal modification A of 1-(2,6-diffuorobenzyi)-1 H-1,2,3-triazole-4-carboxamide melts at 242 C (239-245 C).
In the FT infrared (FT-IR) spectrum (KBr pellet - transmission method), modification A or A' differs from modifications B and C predominantly in the shape and in the relative intensity of many bands. Particularly characteristic are the bands at 3412 cm'' and 3092 cm-' [cf. Figure 1], which are not present in the FT-IR spectra of the -modifications B and C.
In the range 4000-600 cm-', inter alia the following bands are obtained for modification A:
3412, 3189, 3092, 1634, 1560, 1473, 1397, 1325, 1300, 1284, 1235, 1125, 1053, 1036, 1014, 885, 840, 799, 781, 723, 688 and 640 cm'. For example, the apparatus IFS 88 (Bruker) can be used for the recording of each of the FT-IR spectra.
In the FT Raman spectrum (powder - reflection method 180 ); the modification A
or A' differs from modifications B and C predominantly in the shape and in the relative intensity of many bands. Particularly characteristic are the band at 1080 cm" [cf. Figure 2], which is not
AND ITS USE
AS ANTIEPILEPTIC
Background of the invention The compound 1-(2,6-difluorobenzyl)-1 H-1,2,3-triazole-4-carboxamide of the formula O
N
F NN
&F
is described in the European Patent Application with the Publication No. 0 199 (EP 199262), for example in Example 4. Valuable pharmacological properties are attributed to this compound; thus, it can be used, for example, as an antiepileptic. The compound 1-(2,6-difluorobenzyl)-1 H-1,2,3-triazole-4-carboxamide is obtained according to EP 199262, starting from 2,6-difluorobenzyl azide via the formation of 1-(2,6-difluorobenzyl)-1 H-1,2,3-triazole-4-carboxylic acid, the procedure being analogous to Example 2.
EP 199262 provides no information at all about possible crystal modifications obtained. If the method according to the Example 4 is used in conjunction with Example 2, the crude 1-(2,6-difluorobenzyl)-1 H-1,2,3-triazole-4-carboxamide product obtained is finally crystallized from ethanol. However, EP 199262 gives no indication that such recrystallization is specifically to be applied, or on particular conditions that might be adopted.
It has now surprisingly been found that the different crystal modifications (polymorphism) characterized below can be prepared by choice of specially selected process conditions, for example through the choice of an appropriate solvent for the recrystallization or the duration of the recrystallization.
Description of the invention 1-(2,6-Difluorobenzyl)-1 H-1,2,3-triazole-4-carboxamide can be obtained in the novel crystal modifications A, A', B and C. These crystal modifications differ with respect to their thermodynamic stability, in their physical parameters, such as.the absorption pattern of IR
and Raman spectra, in X-ray structure investigations and in their preparation processes.
The invention relates to the novel crystal modifications A and A', their preparation and use in pharmaceutical preparations comprising this crystal modification.
The modification A', compared with A, has defects in the crystal lattice.
These are detectable, for example, by X-ray analysis; e.g. by smaller line spacings with otherwise predominantly identical lines or bands.
The novel crystal modification A of 1-(2,6-diffuorobenzyi)-1 H-1,2,3-triazole-4-carboxamide melts at 242 C (239-245 C).
In the FT infrared (FT-IR) spectrum (KBr pellet - transmission method), modification A or A' differs from modifications B and C predominantly in the shape and in the relative intensity of many bands. Particularly characteristic are the bands at 3412 cm'' and 3092 cm-' [cf. Figure 1], which are not present in the FT-IR spectra of the -modifications B and C.
In the range 4000-600 cm-', inter alia the following bands are obtained for modification A:
3412, 3189, 3092, 1634, 1560, 1473, 1397, 1325, 1300, 1284, 1235, 1125, 1053, 1036, 1014, 885, 840, 799, 781, 723, 688 and 640 cm'. For example, the apparatus IFS 88 (Bruker) can be used for the recording of each of the FT-IR spectra.
In the FT Raman spectrum (powder - reflection method 180 ); the modification A
or A' differs from modifications B and C predominantly in the shape and in the relative intensity of many bands. Particularly characteristic are the band at 1080 cm" [cf. Figure 2], which is not
-3-present in the Raman spectra of the modifications B and C. In the range 3400-300 cm", inter alia the following bands are obtained for the modification A: 3093, 2972, 1628, 1614, 1558, 1465, 1446, 1393, 1279, 1245, 1147, 1080, 1061, 1036, 1014, 840, 724, 691, 667, 550, 499, 437 and 368 cm''. For example, the apparatus RFS 100 (Bruker) can be used for the recording of each of the FT Raman spectra.
The novel modification A has an X-ray powder pattern with characteristic lines with interplanar spacings (d values) of 10.5 A, 5.14 A, 4.84 A, 4.55 A, 4.34 A,
The novel modification A has an X-ray powder pattern with characteristic lines with interplanar spacings (d values) of 10.5 A, 5.14 A, 4.84 A, 4.55 A, 4.34 A,
4.07 A, 3.51 A, 3.48 A, 3.25 A, 3.19 A, 3.15 A, 3.07 A, 2.81 A[cf. Table 1]. The measurement can be carried out, for example, in transmission geometry on an FR 552 Guinier camera from Enraf-Nonius, Delft (The Netherlands), using copper Kal radiation (wavelength X = 1.54060 A). The patterns recorded on X-ray film were measured using an LS-1 8 line scanner from Johannsson, Taby (Sweden) and evaluated using the Scanpi software (P.E.Werner, University of Stockholm).
Characteristic for the novei modification A is the thermogram in differential scanning calorimetry. It has an endothermic peak in the range from 230 C to 260 C.
The peak temperature is 239-245 C, and the endothermic signal is 209 J/g +/- 10 J/g.
The TM
measurement was carried out on a Perkin Elmer DSC 7 in a closed pan with a heating rate of 20 K/minute. The typical sampie quantity is about 4 mg. As a typical distinguishing feature compared with the modifications B and C, the thermogram of the modification A has no further thermal signal.
Crystals fo the modification A' have the same crystal structure as modification A. They differ from the modification A in the X-ray powder pattem in that they have slightly smaller line spacings between specific pairs of lines. These are the pairs of lines with the following interplanar spacings: 3.68 A and 3.64 A, 3.51 A and 3.48 A, 3.19 A and 3.15 A.
In the FT-IR spectrum (KBr pellet - transmission method), the modification B
differs from the modification A or A' and C predominantly in the shape and in the reiative intensity of many bands. Particularly characteristic is a band at 1678 cm"' [cf. Figure 1], which is not to be observed in the corresponding spectra of the modifications A and C. In the range 4000-600 cm", inter alia the following bands are obtained for the modification B:
3404, 3199, 3125, 1678, 1635, 1560, 1475, 1393, 1357, 1322, 1286, 1237, 1051, 1036, 1028, 889, 837, 800, 719, 667 and 645 cm-'. For example, the apparatus IFS 85 (Bruker) can be used for recording of each of the FT-IR spectra.
In the FT Raman spectrum (powder - reflection method 1800), the modification B
differs from the modifications A or A' and C predominantly in the shape and in the relative intensity of many bands. Particularly characteristic are the bands at 3166 cm" and 1086 cm" [cf.
Figure 2], which are not present in the Raman spectra of the modifications A
and C. In the range 3400-300 cm-', inter alia the following bands are obtained for the modification B:
3166, 3089, 2970, 1678, 1628, 1614, 1559, 1464, 1441, 1391, 1275, 1244, 1147, 1086, 1062, 1036, 1014, 839, 773, 724, 690, 668, 595, 549, 500, 493, 430 and 365 cm". For example, the apparatus RFS 100 (Bruker) can be used for recording of each of the FT
Raman spectra.
The modification B has an X-ray powder pattern with characteristic lines with interplanar spacings (d values) of 11.0 A, 8.3 A, 5.18 A, 4.88 A, 4.80 A, 4.42 A, 4.33 A, 4.19 A, 4.12 A, 3.81 A, 3.50 A, 3.41 A, 3.36 A, 3.32 A, 3.28 A, 3.24 A, 3.05 A, 2.83 A[cf.
Table 11.
In the thermogram in differential scanning calorimetry, the modification B
has, in addition to an endothermic signal in the range from 230 C to 260 C (peak temperature 239-245 C), a weak thermal signal at 205 C (180 - 220 C) as a typical distinguishing feature compared with the modifications A or A' and C.
In the FT-IR spectrum (KBr pellet - transmission method), the modification C
differs from the modifications A or A' and B predominantly in the shape and in the relative intensity of many
Characteristic for the novei modification A is the thermogram in differential scanning calorimetry. It has an endothermic peak in the range from 230 C to 260 C.
The peak temperature is 239-245 C, and the endothermic signal is 209 J/g +/- 10 J/g.
The TM
measurement was carried out on a Perkin Elmer DSC 7 in a closed pan with a heating rate of 20 K/minute. The typical sampie quantity is about 4 mg. As a typical distinguishing feature compared with the modifications B and C, the thermogram of the modification A has no further thermal signal.
Crystals fo the modification A' have the same crystal structure as modification A. They differ from the modification A in the X-ray powder pattem in that they have slightly smaller line spacings between specific pairs of lines. These are the pairs of lines with the following interplanar spacings: 3.68 A and 3.64 A, 3.51 A and 3.48 A, 3.19 A and 3.15 A.
In the FT-IR spectrum (KBr pellet - transmission method), the modification B
differs from the modification A or A' and C predominantly in the shape and in the reiative intensity of many bands. Particularly characteristic is a band at 1678 cm"' [cf. Figure 1], which is not to be observed in the corresponding spectra of the modifications A and C. In the range 4000-600 cm", inter alia the following bands are obtained for the modification B:
3404, 3199, 3125, 1678, 1635, 1560, 1475, 1393, 1357, 1322, 1286, 1237, 1051, 1036, 1028, 889, 837, 800, 719, 667 and 645 cm-'. For example, the apparatus IFS 85 (Bruker) can be used for recording of each of the FT-IR spectra.
In the FT Raman spectrum (powder - reflection method 1800), the modification B
differs from the modifications A or A' and C predominantly in the shape and in the relative intensity of many bands. Particularly characteristic are the bands at 3166 cm" and 1086 cm" [cf.
Figure 2], which are not present in the Raman spectra of the modifications A
and C. In the range 3400-300 cm-', inter alia the following bands are obtained for the modification B:
3166, 3089, 2970, 1678, 1628, 1614, 1559, 1464, 1441, 1391, 1275, 1244, 1147, 1086, 1062, 1036, 1014, 839, 773, 724, 690, 668, 595, 549, 500, 493, 430 and 365 cm". For example, the apparatus RFS 100 (Bruker) can be used for recording of each of the FT
Raman spectra.
The modification B has an X-ray powder pattern with characteristic lines with interplanar spacings (d values) of 11.0 A, 8.3 A, 5.18 A, 4.88 A, 4.80 A, 4.42 A, 4.33 A, 4.19 A, 4.12 A, 3.81 A, 3.50 A, 3.41 A, 3.36 A, 3.32 A, 3.28 A, 3.24 A, 3.05 A, 2.83 A[cf.
Table 11.
In the thermogram in differential scanning calorimetry, the modification B
has, in addition to an endothermic signal in the range from 230 C to 260 C (peak temperature 239-245 C), a weak thermal signal at 205 C (180 - 220 C) as a typical distinguishing feature compared with the modifications A or A' and C.
In the FT-IR spectrum (KBr pellet - transmission method), the modification C
differs from the modifications A or A' and B predominantly in the shape and in the relative intensity of many
-5-bands. Particularly characteristic is a band at 3137 cm" [cf. Figure 1), which is not to be observed in the corresponding spectra of the modifications A and B.
In the range 4000-600 cm.', inter alia the following bands are obtained for the modification C: 3396, 3287, 3137, 1657, 1631, 1602, 1559, 1475, 1392, 1323, 1287, 1237, 1122, 1104, 1047, 1035, 1012, 876, 839, 797, 773, 729 and 653 cm". For example, the apparatus IFS
85 (Bruker) can be used for recording of each of the FT-IR spectra.
In the FT Raman spectrum (powder - reflection method 1800), the modification C
differs from the modifications A or A' and B predominantly in the shape and in the relative intensity of many bands. Particularly characteristic are the bands at 3137 cm-' and 1602 cm-' [cf.
Figure 2], which are not present in the Raman spectra of the modifications A
and B. In the range 3400-300 cm", inter alia the following bands are obtained for the modification C:
3137, 3080, 3012, 2971, 1673, 1629, 1602, 1561, 1436, 1271, 1248, 1105, 1065, 1035, 1013, 839, 800, 767, 726, 690, 672, 593, 549, 500, 492, 435 and 370 cm'1. For example, the apparatus RFS 100 (Bruker) can be used for recording of each of the FT
Raman spectra.
The modification C has an X-ray powder pattern with characteristic lines with interplanar spacings (d values) of 9.0 A, 4.73 A, 4.65 A, 3.75 A, 3.54 A, 3.42 A, 3.25 A
[cf. Table 1 ]. In the thermogram in differential scanning calorimetry, the modification C has, in addition to an endothermic signal in the range of 230 C to 260 C (peak temperature 239-245 C), a very broad, weak, exothermic signal in the region of 180 C compared with the modifications A or A' and B.
In the range 4000-600 cm.', inter alia the following bands are obtained for the modification C: 3396, 3287, 3137, 1657, 1631, 1602, 1559, 1475, 1392, 1323, 1287, 1237, 1122, 1104, 1047, 1035, 1012, 876, 839, 797, 773, 729 and 653 cm". For example, the apparatus IFS
85 (Bruker) can be used for recording of each of the FT-IR spectra.
In the FT Raman spectrum (powder - reflection method 1800), the modification C
differs from the modifications A or A' and B predominantly in the shape and in the relative intensity of many bands. Particularly characteristic are the bands at 3137 cm-' and 1602 cm-' [cf.
Figure 2], which are not present in the Raman spectra of the modifications A
and B. In the range 3400-300 cm", inter alia the following bands are obtained for the modification C:
3137, 3080, 3012, 2971, 1673, 1629, 1602, 1561, 1436, 1271, 1248, 1105, 1065, 1035, 1013, 839, 800, 767, 726, 690, 672, 593, 549, 500, 492, 435 and 370 cm'1. For example, the apparatus RFS 100 (Bruker) can be used for recording of each of the FT
Raman spectra.
The modification C has an X-ray powder pattern with characteristic lines with interplanar spacings (d values) of 9.0 A, 4.73 A, 4.65 A, 3.75 A, 3.54 A, 3.42 A, 3.25 A
[cf. Table 1 ]. In the thermogram in differential scanning calorimetry, the modification C has, in addition to an endothermic signal in the range of 230 C to 260 C (peak temperature 239-245 C), a very broad, weak, exothermic signal in the region of 180 C compared with the modifications A or A' and B.
-6- -Table 1: Characterization of the modifications A. B and C (X-ray powder pattems):
Modification.A: Modification-B: Modification C:
_..
d~j .:. lntensi , lntens intensi .
10.9 weak 11.0 medium 9.0 medium 10.5 medium 8.3 medium 7.0 weak 6.6 weak 8.1 very weak 5.49 weak 5.63 weak 5.68 very weak 5.11 ve weak 5.25 weak 5.18 very stron 4.80 weak 5.14 medium 5.11 weak 4 3 strona 4.94 w ak 4.88 medium 4.65 very stron 4.84 very str n 4.80 stron 4.47 verv weak 4.55 stron 4.71 very weak 4.19 ve weak 4.42 ve weak 4.61 weak 4.11 ve weak 4.34 medium 4.45 weak 3.98 very weak 4.23 very weak 4.42 strona 3.83 ve weak 4.16 weak 4.33 very stron 3.75 strona 4.07 medium 4.19 medium 3.73 weak 4.01 weak 4.12 strona 3.54 medium 3.68 ve weak 4.09 weak 3.50 weak 3.64 ve weak 3.99 ve weak 3.42 stron 3.60 weak 3.95 ye-ni weak 3.25 medium 3.56 weak 3.84 weak 2.88 very weak 3.51 medium 3.81 medium 2.80 very weak 3.48 medium 3.65 weak 2.74 very weak 3.38 ve weak 3.61 very weak 2.67 ve weak 3.25 strona 3.58 ve weak 2.64 weak 3.19 medium 3.54 weak 3.15 medium 3.50 medium 3.11 weak 3.47 very weak 3.07 medium 3.41 medium 2.93 very weak 3.36 very strona 2.87 very weak 3.32 strona 2.81 medium 3.28 medium 2.76 weak 3.24 medium 2.73 very weak 3.10 weak 2.68 weak 3.07 weak 2.62 very weak 3.05 medium 2.53 weak 2.93 weak 2.43 weak 2.88 weak 2.40 very weak 2.87 very weak 2.83 medium 2.66 weak 2.63 very weak 2.55 weak 2.50 weak
Modification.A: Modification-B: Modification C:
_..
d~j .:. lntensi , lntens intensi .
10.9 weak 11.0 medium 9.0 medium 10.5 medium 8.3 medium 7.0 weak 6.6 weak 8.1 very weak 5.49 weak 5.63 weak 5.68 very weak 5.11 ve weak 5.25 weak 5.18 very stron 4.80 weak 5.14 medium 5.11 weak 4 3 strona 4.94 w ak 4.88 medium 4.65 very stron 4.84 very str n 4.80 stron 4.47 verv weak 4.55 stron 4.71 very weak 4.19 ve weak 4.42 ve weak 4.61 weak 4.11 ve weak 4.34 medium 4.45 weak 3.98 very weak 4.23 very weak 4.42 strona 3.83 ve weak 4.16 weak 4.33 very stron 3.75 strona 4.07 medium 4.19 medium 3.73 weak 4.01 weak 4.12 strona 3.54 medium 3.68 ve weak 4.09 weak 3.50 weak 3.64 ve weak 3.99 ve weak 3.42 stron 3.60 weak 3.95 ye-ni weak 3.25 medium 3.56 weak 3.84 weak 2.88 very weak 3.51 medium 3.81 medium 2.80 very weak 3.48 medium 3.65 weak 2.74 very weak 3.38 ve weak 3.61 very weak 2.67 ve weak 3.25 strona 3.58 ve weak 2.64 weak 3.19 medium 3.54 weak 3.15 medium 3.50 medium 3.11 weak 3.47 very weak 3.07 medium 3.41 medium 2.93 very weak 3.36 very strona 2.87 very weak 3.32 strona 2.81 medium 3.28 medium 2.76 weak 3.24 medium 2.73 very weak 3.10 weak 2.68 weak 3.07 weak 2.62 very weak 3.05 medium 2.53 weak 2.93 weak 2.43 weak 2.88 weak 2.40 very weak 2.87 very weak 2.83 medium 2.66 weak 2.63 very weak 2.55 weak 2.50 weak
-7-2.46 weak 2.44 weak 2.37 weak Single cr rLstal X-ray analysis:
Crystal quality and unit cell of modifications A, B, and C were verified by Weissenberg and precession photographs. The intensities were measured on a four-axis Nonius diffractometer. The structures were solved with the SHELXS-97 and refined with the SHELXL-97 software.
Modification A
Space group: Pna2, - orthorhombic Cell dimensions:
a = 24.756 (5)A b = 23.069 (4)A c = 5.386 (1)A
v= 3075.9 A3 Z= 12 Dx = 1.543 gcm-3 v per formula: VZ = 256.3 A3 9011 unique reflections; 2479 thereof significant with I> 20 (I). 557 parameters refined.
Position of all H atoms found by difference Fourier maps and refined isotropically.
Reliability index R,: 3.65% (wR2 for all 9011 reflections: 11.34%).
Modification B
Space group: P '1 -triclinic Cell dimensions:
a = 5.326(1) A b = 11.976(2) A c = 17.355(3) A
a= 107.22(3) (3 = 92.17(3)0 y= 102.11(3) v= 1027.9 A3 Z= 4 Dx = 1.539 gcm'3 v per formula V= = 257.0 A3
Crystal quality and unit cell of modifications A, B, and C were verified by Weissenberg and precession photographs. The intensities were measured on a four-axis Nonius diffractometer. The structures were solved with the SHELXS-97 and refined with the SHELXL-97 software.
Modification A
Space group: Pna2, - orthorhombic Cell dimensions:
a = 24.756 (5)A b = 23.069 (4)A c = 5.386 (1)A
v= 3075.9 A3 Z= 12 Dx = 1.543 gcm-3 v per formula: VZ = 256.3 A3 9011 unique reflections; 2479 thereof significant with I> 20 (I). 557 parameters refined.
Position of all H atoms found by difference Fourier maps and refined isotropically.
Reliability index R,: 3.65% (wR2 for all 9011 reflections: 11.34%).
Modification B
Space group: P '1 -triclinic Cell dimensions:
a = 5.326(1) A b = 11.976(2) A c = 17.355(3) A
a= 107.22(3) (3 = 92.17(3)0 y= 102.11(3) v= 1027.9 A3 Z= 4 Dx = 1.539 gcm'3 v per formula V= = 257.0 A3
-8-4934 unique reflections; 834 thereof significant with I > 20 (1). 232 parameters refined.
Position of all H atoms found by difference Fourier maps and refined isotropically.
Reliability index R,: 4.20% (wR2 for all 4934 reflections: 7.93%).
Modification C
Space group: P21/C - monoclinic Cell dimensions:
a = 10.982(2) A b = 5.350(1) A c- 17.945(3) A
(3 = 91.59(1) v= 1053.9 A3 Z= 4 Dx = 1.501 gcm,3 v per formula: VZ = 263.5 A3 3073 unique reflections; 1071 thereof significant with I > 20 (I). 187 parameters refined.
Position of all H atoms found by difference Fourier maps and refined isotropically.
Reliability index R,: 5,02% (wR2 for all 3073 reflections: 14.55%).
Modifications A, A', B and C have valuable pharmacological properties; in particular, they can be used for the treatment of epilepsy.
The modification A or A' has significant advantages compared with the modification B and compared with the modification C. Thus, for example, comprehensive thermodynamic investigations, such as thermomicroscopy, X-ray powder diffractometry, DSC, solubility tests and other experiments, have shown that the modification A or A' surprisingly has substantially better thermodynamic stability than the modifications B and C.
Modification C, which can be obtained only under specific conditions, is the least stable of the three modifications. The crystals of the modification C are converted into modification B at as low as room temperature within a few weeks. The modification C is converted either into the modification A or A' or into the modification B, depending on experimental conditions.
Position of all H atoms found by difference Fourier maps and refined isotropically.
Reliability index R,: 4.20% (wR2 for all 4934 reflections: 7.93%).
Modification C
Space group: P21/C - monoclinic Cell dimensions:
a = 10.982(2) A b = 5.350(1) A c- 17.945(3) A
(3 = 91.59(1) v= 1053.9 A3 Z= 4 Dx = 1.501 gcm,3 v per formula: VZ = 263.5 A3 3073 unique reflections; 1071 thereof significant with I > 20 (I). 187 parameters refined.
Position of all H atoms found by difference Fourier maps and refined isotropically.
Reliability index R,: 5,02% (wR2 for all 3073 reflections: 14.55%).
Modifications A, A', B and C have valuable pharmacological properties; in particular, they can be used for the treatment of epilepsy.
The modification A or A' has significant advantages compared with the modification B and compared with the modification C. Thus, for example, comprehensive thermodynamic investigations, such as thermomicroscopy, X-ray powder diffractometry, DSC, solubility tests and other experiments, have shown that the modification A or A' surprisingly has substantially better thermodynamic stability than the modifications B and C.
Modification C, which can be obtained only under specific conditions, is the least stable of the three modifications. The crystals of the modification C are converted into modification B at as low as room temperature within a few weeks. The modification C is converted either into the modification A or A' or into the modification B, depending on experimental conditions.
-9- _ It is particularly important for drug that its pharmaceutical formulation ensures high and reproducible stability over a long period. These preconditions are fulfilled by incorporation of the compound 1-(2,6-difluorobenzyl)-1 H-1,2,3-triazole-4-carboxamide of the crystal modification A or A', owing to its high thermodynamic stability. In particular, this is displayed in a solid pharmaceutical dosage form.
A constant stability also permits reproducible bioavailability of an active ingredient. If an active ingredient is subjected to a conversion process, this may readily also cause the bioavailability to fluctuate, which is undesirable. Accordingly, pharmaceutical active ingredients or poiymorphic forms thereof which are of primary interest for pharmaceutical developments are those which exhibit high stability and do not have the above-mentioned disadvantages. The crystal modification A or A' fulfils these preconditions.
Furthermore, the modification A or A' has, for example, a slower dissolution rate in water or in gastric fluid (so-called "slow-release effect"). This effect can be utilized primarily for long-term therapy where a slow or delayed release is desired.
The invention relates to the modification A of 1-(2,6-difluorobenzyl)-1 H-1,2,3-triazole-4-carboxamide, characterized by the following absorptions in the infrared spectrum (KBr pellet - transmission method): bands at 3092 cm-' and 3412 cm".
The invention relates to the modification A of 1-(2,6-difluorobenzy{)-1 H-1,2,3-triazole-4-carboxamide, characterized by characteristic lines with interplanar spacings (d values) of
A constant stability also permits reproducible bioavailability of an active ingredient. If an active ingredient is subjected to a conversion process, this may readily also cause the bioavailability to fluctuate, which is undesirable. Accordingly, pharmaceutical active ingredients or poiymorphic forms thereof which are of primary interest for pharmaceutical developments are those which exhibit high stability and do not have the above-mentioned disadvantages. The crystal modification A or A' fulfils these preconditions.
Furthermore, the modification A or A' has, for example, a slower dissolution rate in water or in gastric fluid (so-called "slow-release effect"). This effect can be utilized primarily for long-term therapy where a slow or delayed release is desired.
The invention relates to the modification A of 1-(2,6-difluorobenzyl)-1 H-1,2,3-triazole-4-carboxamide, characterized by the following absorptions in the infrared spectrum (KBr pellet - transmission method): bands at 3092 cm-' and 3412 cm".
The invention relates to the modification A of 1-(2,6-difluorobenzy{)-1 H-1,2,3-triazole-4-carboxamide, characterized by characteristic lines with interplanar spacings (d values) of
10.5A,5.14A,4.84A,4.55A,4.34A,4.07A,3.51 A,3.48A,3.25A,3.19A,3.15A,3.07 A and 2.81 A, determined by means of an X-ray powder pattern.
The invention relates to the modification A of 1-(2,6-difluorobenzyl)-1 H-1,2,3-triazole-4-carboxamide, characterized by the characteristic lines with interplanar spacings (d values) ------- -----as shown in Table 1.
The invention relates to the modification A of 1-(2,6-difluorobenzyl)-1 H-1,2,3-triazole-4-carboxamide, characterized by an endothermic peak in the range from 230 C to 260 C, the peak temperature being 239-245 C and the endothermic signal being 209 J/g +/- 10 J/g.
Furthermore, the invention relates to the crystal modification A' which, compared with modification A, has defects in the crystal lattice.
The invention relates to the modification A' which, compared with modification A, has smaller line spacings between the pairs of lines with interplanar spacings 3.68 A and 3.64 A,3.51 Aand 3.48A, and 3.19 Aand3.15A.
The invention relates to the essentially pure form of the modification A or A' of 1-(2,6-difluorobenzyl)-1 H-1,2,3-triazole-4-carboxamide. The term "essentially pure form" means purity of >95%, in particular >98%, primarily >99%, based on the modification A or A'.
The invention relates to pharmaceutical preparations comprising the modification A or A' of 1-(2,6-difluorobenzyl)-1 H-1,2,3-triazole-4-carboxamide. The invention relates in particular to corresponding pharmaceutical preparations for the treatment of epilepsy and subindications thereof. The invention relates to the use of the modification A or A' of 1-(2,6-difluorobenzyl)-1 H-1,2,3-triazole-4-carboxamide for the preparation of pharmaceutical preparations, in particular for the treatment of epilepsy and subindications thereof.
The novel modification A or A' of 1-(2,6-difluorobenzyl)-1 H-1,2,3-triazole-4-carboxamide can be used, for example, in the form of pharmaceutical preparations which comprise a therapeutically effective amount of the active ingredient, if desired together with inorganic or organic, solid or liquid, pharmaceutically usable carriers, which are suitable for enteral, for -i1- _ example oral, or parenteral administration. Furthermore, the novel modification A or A' of 1-(2,6-difluorobenzyl)-1 H-1,2,3-triazole-4-carboxamide can be used in the form of preparations which can be administered parenterally or of infusion solutions.
The pharmaceutical preparations may be sterilized and/or may comprise excipients, for example preservatives, stabilizers, wetting agents and/or emulsifiers, solubilizers, salts for regulating the osmotic pressure and/or buffers. The present pharmaceutical preparations comprise from about 0.1 % to 100%, in particular from about 1% to about 50%, of lyophilisates to about 100% of the active ingredient.
The invention also relates to the use of modification A or A' of 1-(2,6-difluorobenzyl)-1H-1,2,3-triazole-4-carboxamide as a drug, preferably in the form of pharmaceutical preparations. The dosage may depend on various factors, such as method of administration, species, age and/or individuai condition. The doses to be administered daily are between about 0.25 and about 10 mg/kg in the case of oral administration, and preferably between about 20 mg and about 500 mg for warm-blooded species having a body weight of about 70 kg.
The preparation of modification A or A' is carried out, for example, as described in the embodiments below.
Preparation of 1-(2.6-difluorobenzyll-1 H-1.2.3-triazole-4-carboxamide Example 1:
A suspension of methyl 1-(2,6-difluorobenzyl)-1 H-1,2,3-triazole-4-carboxylate (about 62 parts by weight), methanol (475.2 parts by weight) and anhydrous ammonia (29.4 parts by weight) is stirred for about 24 hours at 50-55 C in a closed vessel. The suspension is cooled to about 20 C and stirred for about a further 2 hours. The product is isolated by filtration, washed with methanol (240 parts by weight) and dried at 40-60 C in vacuo. Yield:
57.2 parts by weight = 98%. Modification A.
The starting compounds can be prepared, for example, as follows:
mixture of 1-(2,6-difluorobenzyl)-1 H-1,2,3-triazote-4-carboxylic acid (167.1 parts by A
weight), methanol (552 parts by weight) and 96% sulfuric acid (35.7 parts by weight) is stirred for about 5 hours at 60-66 C. The suspension is cooled to about 20 C
and stirred for about a further 2 hours. The product is isolated by filtration and washed with methanol (198 parts by weight). A yield of about 160 parts by weight is obtained by drying at 40-60 C in vacuo.
Example 2:
1 N sodium hydroxide solution (0.11 ml) is added to a mixture of 4-cyano-1-(2,6-diftuorobenzyt)-1 H-1,2,3-triazole (2.20 g) and water (44 ml) at an externat temperature of 95-100 C while stirring. After 90 minutes, the suspension is cooled to 10 C and the product is isolated by filtration, washed with water and dried at about 60 C in vacuo. 1-(2,6-Difluorobenzyl)-1H-1,2,3-triazole-4-carboxamide is obtained in this manner; yield: 99.2% by weight.
Modification A.
The starting material can be prepared, for example, as follows:
4-Cyano-1-(2,6-difluorobenzyl)-1 H-1,2,3-triazole A mixture of 2,6-difluorobenzyt azide (34.2 g), 2-chloroacrytonitrile (17.73 g) and water (125 ml) is stirred for 24 hours at about 80 C. By increasing the extemal temperature to about 130 C, excess 2-chloroacrylonitrile is distilled off. The semisolid mixture is cooled to about 40 C, cyclohexane (50 ml) is added to the suspension and the mixture is brought to about 20 C and stirred for about 2 hours. The product is isolated by filtration and washed with cyclohexane (75 mi) and then with water (50 ml). The moist product is mixed with water (100 ml), the suspension is filtered and the product is washed with water (50 ml) and dried at about 60 C in vacuo. Yield:
38.04 g = 86%.
Exampies of the recrystallization of 1-(2,6-difluorobenzkl)-1 H-1,2.3-triazole-4-carboxamide Example 3:
1-(2,6-Difluorobenzyl)-1 H-1,2,3-triazole-4-carboxamide (75.0 g) is dissolved in formic acid (360 ml) at 50-55 C by stirring. The solution is discharged in the course of 1 hour onto stirred methanol (375 ml) at about 20 C, a suspension forming. After stirring has been continued for 2 hours at about 20 C, the product is isolated by filtration, washed with methanol (750 ml) and dried at about 60 C in vacuo. Yield: 69.6 g = 92.8%.
Modification A.
Example 4:
1-(2,6-Difluorobenzyl)-1 H-1,2,3-triazole-4-carboxamide (22.86 kg) is dissolved in formic acid (111.6 kg) at 58-63 C while stirring. The solution is discharged in the course of about 2 hours onto stirred methanol (131.9 I) at 20-25 C, after which washing with formic acid (7.6 kg) is carried out. A suspension forms. After stirring has been continued for at least 3 hours at about 20 C, the product is isolated by filtration and washed with methanol (187.5 I). By drying in vacuo at about 60 C, the product is obtained as modification A in a yield of 93-94%.
Example 5:
1-(2,6-difluorobenzyl)-1 H-1,2,3-triazole-4-carboxamide (pure active ingredient; 4.0 g) is dissolved in 96% ethanol (500 mi, without denaturing agent) at about 80 C
while stirring. The solution is filtered into a suction bottle (1 litre) at about 20 C (glass suction filter, pore size 10-20 pm), a suspension forming. After stirring has been continued for 5 minutes at about 20 C and for 15 minutes at about 0 C, the product is isolated by filtration (about 0 to about 20 C). The solvent-moist product (9.6 g) is investigated without subsequent drying.
Modification A'.
Formulation Example 1:
Film-coated tablets each containing, for example, 100, 200 or 400 mg of modification A or A' of 1-(2,6-difluorobenzyl)-1 H-1,2,3-triazole-4-carboxamide with the following composition per dosage unit:
Core material mg mg mg Active ingredient 100.00 200.00 400.00 Anhydrous, colloidal silica 0.88 1.75 3.5 Microcrystalline cellulose 36.62 73.25 146.50 Hydroxypropylmethyl- 5.00 10.00 20.00 cellulose Lactose 20.00 40.00 80.00 Magnesium stearate 2.00 4.00 8.00 Maize starch 10.00 20.00 40.00 Sodium carboxymethyl- 5.00 10.00 20.00 cellulose Sodium laurylsulfate 0.50 1.00 2.00 Film coat mg mg mg Hydroxypropylmethyl- 3.22 6.43 12.87 cellulose Red iron oxide 0.04 0.09 0.18 Polyethylene glycol 8000, 0.58 1.16 2.32 flakes Talc 2.33 4.66 9.31 Titanium dioxide 0.83 1.66 3.32 The active ingredient is granulated with demineralised water. Milled lactose, maize starch, TM
Avicel PH 102, cellulose-HP-M-603 and sodium lauryisulfate are added to the above mixture and granulated with demineralised water.
The moist material is dried and milled. After the addition of the remaining ingredients, the homogeneous mixture is compressed to give tablet cores having the stated active ingredient content.
The tablet cores are coated with the film coat which is formed from the appropriate ingredients, the latter being dissolved or being suspended in water or in small amounts of ethanol with 5% of isopropanol.
Description of the Figures Figure 1 shows the FT-IR spectra of the KBr pellets of modifications A, B and C.
Figure 2 shows the FT-Raman spectra of the powder of modification A, B and C.
In both Figures, the modification A is denoted by the symbol R, the modification B by the symbol "' and the modification C by the symbol ""
The invention relates to the modification A of 1-(2,6-difluorobenzyl)-1 H-1,2,3-triazole-4-carboxamide, characterized by the characteristic lines with interplanar spacings (d values) ------- -----as shown in Table 1.
The invention relates to the modification A of 1-(2,6-difluorobenzyl)-1 H-1,2,3-triazole-4-carboxamide, characterized by an endothermic peak in the range from 230 C to 260 C, the peak temperature being 239-245 C and the endothermic signal being 209 J/g +/- 10 J/g.
Furthermore, the invention relates to the crystal modification A' which, compared with modification A, has defects in the crystal lattice.
The invention relates to the modification A' which, compared with modification A, has smaller line spacings between the pairs of lines with interplanar spacings 3.68 A and 3.64 A,3.51 Aand 3.48A, and 3.19 Aand3.15A.
The invention relates to the essentially pure form of the modification A or A' of 1-(2,6-difluorobenzyl)-1 H-1,2,3-triazole-4-carboxamide. The term "essentially pure form" means purity of >95%, in particular >98%, primarily >99%, based on the modification A or A'.
The invention relates to pharmaceutical preparations comprising the modification A or A' of 1-(2,6-difluorobenzyl)-1 H-1,2,3-triazole-4-carboxamide. The invention relates in particular to corresponding pharmaceutical preparations for the treatment of epilepsy and subindications thereof. The invention relates to the use of the modification A or A' of 1-(2,6-difluorobenzyl)-1 H-1,2,3-triazole-4-carboxamide for the preparation of pharmaceutical preparations, in particular for the treatment of epilepsy and subindications thereof.
The novel modification A or A' of 1-(2,6-difluorobenzyl)-1 H-1,2,3-triazole-4-carboxamide can be used, for example, in the form of pharmaceutical preparations which comprise a therapeutically effective amount of the active ingredient, if desired together with inorganic or organic, solid or liquid, pharmaceutically usable carriers, which are suitable for enteral, for -i1- _ example oral, or parenteral administration. Furthermore, the novel modification A or A' of 1-(2,6-difluorobenzyl)-1 H-1,2,3-triazole-4-carboxamide can be used in the form of preparations which can be administered parenterally or of infusion solutions.
The pharmaceutical preparations may be sterilized and/or may comprise excipients, for example preservatives, stabilizers, wetting agents and/or emulsifiers, solubilizers, salts for regulating the osmotic pressure and/or buffers. The present pharmaceutical preparations comprise from about 0.1 % to 100%, in particular from about 1% to about 50%, of lyophilisates to about 100% of the active ingredient.
The invention also relates to the use of modification A or A' of 1-(2,6-difluorobenzyl)-1H-1,2,3-triazole-4-carboxamide as a drug, preferably in the form of pharmaceutical preparations. The dosage may depend on various factors, such as method of administration, species, age and/or individuai condition. The doses to be administered daily are between about 0.25 and about 10 mg/kg in the case of oral administration, and preferably between about 20 mg and about 500 mg for warm-blooded species having a body weight of about 70 kg.
The preparation of modification A or A' is carried out, for example, as described in the embodiments below.
Preparation of 1-(2.6-difluorobenzyll-1 H-1.2.3-triazole-4-carboxamide Example 1:
A suspension of methyl 1-(2,6-difluorobenzyl)-1 H-1,2,3-triazole-4-carboxylate (about 62 parts by weight), methanol (475.2 parts by weight) and anhydrous ammonia (29.4 parts by weight) is stirred for about 24 hours at 50-55 C in a closed vessel. The suspension is cooled to about 20 C and stirred for about a further 2 hours. The product is isolated by filtration, washed with methanol (240 parts by weight) and dried at 40-60 C in vacuo. Yield:
57.2 parts by weight = 98%. Modification A.
The starting compounds can be prepared, for example, as follows:
mixture of 1-(2,6-difluorobenzyl)-1 H-1,2,3-triazote-4-carboxylic acid (167.1 parts by A
weight), methanol (552 parts by weight) and 96% sulfuric acid (35.7 parts by weight) is stirred for about 5 hours at 60-66 C. The suspension is cooled to about 20 C
and stirred for about a further 2 hours. The product is isolated by filtration and washed with methanol (198 parts by weight). A yield of about 160 parts by weight is obtained by drying at 40-60 C in vacuo.
Example 2:
1 N sodium hydroxide solution (0.11 ml) is added to a mixture of 4-cyano-1-(2,6-diftuorobenzyt)-1 H-1,2,3-triazole (2.20 g) and water (44 ml) at an externat temperature of 95-100 C while stirring. After 90 minutes, the suspension is cooled to 10 C and the product is isolated by filtration, washed with water and dried at about 60 C in vacuo. 1-(2,6-Difluorobenzyl)-1H-1,2,3-triazole-4-carboxamide is obtained in this manner; yield: 99.2% by weight.
Modification A.
The starting material can be prepared, for example, as follows:
4-Cyano-1-(2,6-difluorobenzyl)-1 H-1,2,3-triazole A mixture of 2,6-difluorobenzyt azide (34.2 g), 2-chloroacrytonitrile (17.73 g) and water (125 ml) is stirred for 24 hours at about 80 C. By increasing the extemal temperature to about 130 C, excess 2-chloroacrylonitrile is distilled off. The semisolid mixture is cooled to about 40 C, cyclohexane (50 ml) is added to the suspension and the mixture is brought to about 20 C and stirred for about 2 hours. The product is isolated by filtration and washed with cyclohexane (75 mi) and then with water (50 ml). The moist product is mixed with water (100 ml), the suspension is filtered and the product is washed with water (50 ml) and dried at about 60 C in vacuo. Yield:
38.04 g = 86%.
Exampies of the recrystallization of 1-(2,6-difluorobenzkl)-1 H-1,2.3-triazole-4-carboxamide Example 3:
1-(2,6-Difluorobenzyl)-1 H-1,2,3-triazole-4-carboxamide (75.0 g) is dissolved in formic acid (360 ml) at 50-55 C by stirring. The solution is discharged in the course of 1 hour onto stirred methanol (375 ml) at about 20 C, a suspension forming. After stirring has been continued for 2 hours at about 20 C, the product is isolated by filtration, washed with methanol (750 ml) and dried at about 60 C in vacuo. Yield: 69.6 g = 92.8%.
Modification A.
Example 4:
1-(2,6-Difluorobenzyl)-1 H-1,2,3-triazole-4-carboxamide (22.86 kg) is dissolved in formic acid (111.6 kg) at 58-63 C while stirring. The solution is discharged in the course of about 2 hours onto stirred methanol (131.9 I) at 20-25 C, after which washing with formic acid (7.6 kg) is carried out. A suspension forms. After stirring has been continued for at least 3 hours at about 20 C, the product is isolated by filtration and washed with methanol (187.5 I). By drying in vacuo at about 60 C, the product is obtained as modification A in a yield of 93-94%.
Example 5:
1-(2,6-difluorobenzyl)-1 H-1,2,3-triazole-4-carboxamide (pure active ingredient; 4.0 g) is dissolved in 96% ethanol (500 mi, without denaturing agent) at about 80 C
while stirring. The solution is filtered into a suction bottle (1 litre) at about 20 C (glass suction filter, pore size 10-20 pm), a suspension forming. After stirring has been continued for 5 minutes at about 20 C and for 15 minutes at about 0 C, the product is isolated by filtration (about 0 to about 20 C). The solvent-moist product (9.6 g) is investigated without subsequent drying.
Modification A'.
Formulation Example 1:
Film-coated tablets each containing, for example, 100, 200 or 400 mg of modification A or A' of 1-(2,6-difluorobenzyl)-1 H-1,2,3-triazole-4-carboxamide with the following composition per dosage unit:
Core material mg mg mg Active ingredient 100.00 200.00 400.00 Anhydrous, colloidal silica 0.88 1.75 3.5 Microcrystalline cellulose 36.62 73.25 146.50 Hydroxypropylmethyl- 5.00 10.00 20.00 cellulose Lactose 20.00 40.00 80.00 Magnesium stearate 2.00 4.00 8.00 Maize starch 10.00 20.00 40.00 Sodium carboxymethyl- 5.00 10.00 20.00 cellulose Sodium laurylsulfate 0.50 1.00 2.00 Film coat mg mg mg Hydroxypropylmethyl- 3.22 6.43 12.87 cellulose Red iron oxide 0.04 0.09 0.18 Polyethylene glycol 8000, 0.58 1.16 2.32 flakes Talc 2.33 4.66 9.31 Titanium dioxide 0.83 1.66 3.32 The active ingredient is granulated with demineralised water. Milled lactose, maize starch, TM
Avicel PH 102, cellulose-HP-M-603 and sodium lauryisulfate are added to the above mixture and granulated with demineralised water.
The moist material is dried and milled. After the addition of the remaining ingredients, the homogeneous mixture is compressed to give tablet cores having the stated active ingredient content.
The tablet cores are coated with the film coat which is formed from the appropriate ingredients, the latter being dissolved or being suspended in water or in small amounts of ethanol with 5% of isopropanol.
Description of the Figures Figure 1 shows the FT-IR spectra of the KBr pellets of modifications A, B and C.
Figure 2 shows the FT-Raman spectra of the powder of modification A, B and C.
In both Figures, the modification A is denoted by the symbol R, the modification B by the symbol "' and the modification C by the symbol ""
Claims
CLAIMS:
1. Crystal modification A of the compound 1-(2,6-difluorobenzyl)-1H-1,2,3-triazole-4-carboxamide of the formula characterized by characteristic lines at interplanar spacings (d values) of 10.5.ANG., 5.14 .ANG., 4.84 .ANG., 4.55 .ANG., 4.34 .ANG.,351 .ANG., 3.48 .ANG., 3.25 .ANG., 3.19 .ANG., 3.15 .ANG., 3.97 .ANG., 2.81 .ANG., determined by means of an X-ray powder pattern.
2. Crystal modification according to claim 1, characterized by an X-ray powder pattern having the following characteristic lines at interplanar spacings (d values) of 10.9 .ANG. (weak), 10.5 .ANG.
(medium), 6.6 .ANG.(weak), 5.63 .ANG.(weak), 5.25 .ANG. (weak), 5.14 .ANG.
(medium), 4.94 .ANG. (weak), 4.84 .ANG. (very strong), 4.55 .ANG. (strong), 4.42 .ANG.(very weak), 4.34 .ANG. (medium), 4.23 .ANG. (very weak), 4.16 .ANG. (weak), 4.07 .ANG. (medium), 4.01 .ANG. (weak), 3.68 .ANG.
(very weak), 3.64 .ANG. (very weak), 3.60 .ANG. (weak), 3.56 .ANG. (weak), 3.51 .ANG. (medium), 3.48 .ANG.
(medium), 3.38 .ANG. (very weak), 3.25 .ANG. (strong), 3.19 .ANG. (medium), 3.15 .ANG. (medium), 3.11 .ANG. (weak), 3.07 .ANG. (medium), 2.93 .ANG. (very weak), 2.87 .ANG.(very weak), 2.81 .ANG. (medium), 2.76 .ANG.
(weak), 2.73 .ANG. (very weak), 2.68 .ANG. (weak), 2.62 .ANG. (very weak), 2.53 .ANG. (weak), 2.43 (weak), 2.40 .ANG. (very weak).
4. Crystal modification according to claim 3, characterized by the following absorptions in the FT-IR
spectrum (KBr pellet - transmission method): 3412, 3189, 3092, 1634, 1560, 1473, 1397, 1325, 1300, 1284, 1235, 1125, 1053, 1036, 1014, 885, 840, 799, 781, 723, 688 and 640 cm-1.
5. Crystal modification according to any one of claims 1-4, characterized by the following absorptions in the FT-Raman spectrum (powder - reflection method 180°):
3093, 2972, 1628, 1614, 1558, 1465, 1446, 1393, 1279, 1245, 1147, 1080, 1061, 1036, 1014, 840, 724, 691, 667, 550, 499, 437 and 368 cm-1.
6. Crystal modification A according to any one of claims 1-5, characterized by an endothermic peak in the range from 230°C to 260°C, the peak temperature being 239-245°C and the endothermic signal being 209 J/g +/- 10 J/g.
7. Crystal modification A according to any one of claims 1 to 6 having a purity in excess of 95%.
8. A pharmaceutical composition comprising crystal modification A according to any one of claims 1 to 7 and a pharmaceutically acceptable carrier or diluent.
9. A pharmaceutical composition according to claim 8 for treatment of epilepsy, or a subindication thereof.
10. Use of crystal modification A according to any one of claims 1 to 7 in preparation of a pharmaceutical composition for treating epilepsy or a subindication thereof.
11. Use of crystal modification A according to any one of claims 1 to 7 for treating epilepsy or a subindication thereof.
12. Crystal modification A according to any one of claims 1 to 7 for treating epilepsy or a subindication thereof.
1. Crystal modification A of the compound 1-(2,6-difluorobenzyl)-1H-1,2,3-triazole-4-carboxamide of the formula characterized by characteristic lines at interplanar spacings (d values) of 10.5.ANG., 5.14 .ANG., 4.84 .ANG., 4.55 .ANG., 4.34 .ANG.,351 .ANG., 3.48 .ANG., 3.25 .ANG., 3.19 .ANG., 3.15 .ANG., 3.97 .ANG., 2.81 .ANG., determined by means of an X-ray powder pattern.
2. Crystal modification according to claim 1, characterized by an X-ray powder pattern having the following characteristic lines at interplanar spacings (d values) of 10.9 .ANG. (weak), 10.5 .ANG.
(medium), 6.6 .ANG.(weak), 5.63 .ANG.(weak), 5.25 .ANG. (weak), 5.14 .ANG.
(medium), 4.94 .ANG. (weak), 4.84 .ANG. (very strong), 4.55 .ANG. (strong), 4.42 .ANG.(very weak), 4.34 .ANG. (medium), 4.23 .ANG. (very weak), 4.16 .ANG. (weak), 4.07 .ANG. (medium), 4.01 .ANG. (weak), 3.68 .ANG.
(very weak), 3.64 .ANG. (very weak), 3.60 .ANG. (weak), 3.56 .ANG. (weak), 3.51 .ANG. (medium), 3.48 .ANG.
(medium), 3.38 .ANG. (very weak), 3.25 .ANG. (strong), 3.19 .ANG. (medium), 3.15 .ANG. (medium), 3.11 .ANG. (weak), 3.07 .ANG. (medium), 2.93 .ANG. (very weak), 2.87 .ANG.(very weak), 2.81 .ANG. (medium), 2.76 .ANG.
(weak), 2.73 .ANG. (very weak), 2.68 .ANG. (weak), 2.62 .ANG. (very weak), 2.53 .ANG. (weak), 2.43 (weak), 2.40 .ANG. (very weak).
4. Crystal modification according to claim 3, characterized by the following absorptions in the FT-IR
spectrum (KBr pellet - transmission method): 3412, 3189, 3092, 1634, 1560, 1473, 1397, 1325, 1300, 1284, 1235, 1125, 1053, 1036, 1014, 885, 840, 799, 781, 723, 688 and 640 cm-1.
5. Crystal modification according to any one of claims 1-4, characterized by the following absorptions in the FT-Raman spectrum (powder - reflection method 180°):
3093, 2972, 1628, 1614, 1558, 1465, 1446, 1393, 1279, 1245, 1147, 1080, 1061, 1036, 1014, 840, 724, 691, 667, 550, 499, 437 and 368 cm-1.
6. Crystal modification A according to any one of claims 1-5, characterized by an endothermic peak in the range from 230°C to 260°C, the peak temperature being 239-245°C and the endothermic signal being 209 J/g +/- 10 J/g.
7. Crystal modification A according to any one of claims 1 to 6 having a purity in excess of 95%.
8. A pharmaceutical composition comprising crystal modification A according to any one of claims 1 to 7 and a pharmaceutically acceptable carrier or diluent.
9. A pharmaceutical composition according to claim 8 for treatment of epilepsy, or a subindication thereof.
10. Use of crystal modification A according to any one of claims 1 to 7 in preparation of a pharmaceutical composition for treating epilepsy or a subindication thereof.
11. Use of crystal modification A according to any one of claims 1 to 7 for treating epilepsy or a subindication thereof.
12. Crystal modification A according to any one of claims 1 to 7 for treating epilepsy or a subindication thereof.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CH140497 | 1997-06-10 | ||
CH1404/97 | 1997-06-10 | ||
PCT/EP1998/003427 WO1998056772A1 (en) | 1997-06-10 | 1998-06-08 | Crystal modification of 1-(2,6-difluorobenzyl)-1h-1,2,3--triazole-4-carboxamide and its use as antiepileptic |
Publications (2)
Publication Number | Publication Date |
---|---|
CA2256013A1 CA2256013A1 (en) | 1998-12-17 |
CA2256013C true CA2256013C (en) | 2007-10-16 |
Family
ID=4209650
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA002256015A Expired - Lifetime CA2256015C (en) | 1997-06-10 | 1998-06-08 | Crystal modification of 1-(2,6-difluorobenzyl)-1h-1,2,3-triazole-4-carboxamide and its use as antiepileptic |
CA002256013A Expired - Lifetime CA2256013C (en) | 1997-06-10 | 1998-06-08 | Crystal modification of 1-(2,6-difluorobenzyl)-1h-1,2,3-triazole-4-carboxamide and its use as antiepileptic |
CA2614926A Expired - Lifetime CA2614926C (en) | 1997-06-10 | 1998-06-08 | Crystal modification c of 1-(2,6-difluorobenzyl)-1h-1,2,3-triazole-4-carboxamide and its use as antiepileptic |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA002256015A Expired - Lifetime CA2256015C (en) | 1997-06-10 | 1998-06-08 | Crystal modification of 1-(2,6-difluorobenzyl)-1h-1,2,3-triazole-4-carboxamide and its use as antiepileptic |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA2614926A Expired - Lifetime CA2614926C (en) | 1997-06-10 | 1998-06-08 | Crystal modification c of 1-(2,6-difluorobenzyl)-1h-1,2,3-triazole-4-carboxamide and its use as antiepileptic |
Country Status (37)
Country | Link |
---|---|
US (6) | US6740669B1 (en) |
EP (2) | EP0994864B1 (en) |
JP (2) | JP3672574B2 (en) |
KR (2) | KR100409168B1 (en) |
CN (3) | CN1298708C (en) |
AR (4) | AR012946A1 (en) |
AT (2) | ATE232852T1 (en) |
AU (2) | AU725517B2 (en) |
BR (2) | BR9804947A (en) |
CA (3) | CA2256015C (en) |
CO (2) | CO4940448A1 (en) |
CY (1) | CY2007014I2 (en) |
CZ (2) | CZ292260B6 (en) |
DE (3) | DE122007000051I2 (en) |
DK (2) | DK0994863T3 (en) |
ES (2) | ES2197485T3 (en) |
FR (1) | FR07C0037I2 (en) |
HK (3) | HK1028242A1 (en) |
HU (2) | HU225153B1 (en) |
ID (2) | ID21014A (en) |
IL (2) | IL125732A (en) |
LU (1) | LU91345I2 (en) |
MY (2) | MY125854A (en) |
NL (1) | NL300284I2 (en) |
NO (2) | NO329314B1 (en) |
NZ (2) | NZ331371A (en) |
PE (2) | PE79799A1 (en) |
PL (2) | PL191943B1 (en) |
PT (1) | PT994864E (en) |
RU (2) | RU2194041C2 (en) |
SI (2) | SI0994864T1 (en) |
SK (2) | SK283734B6 (en) |
TR (2) | TR199801631T1 (en) |
TW (2) | TW526195B (en) |
UY (1) | UY25844A1 (en) |
WO (2) | WO1998056772A1 (en) |
ZA (2) | ZA984967B (en) |
Families Citing this family (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TW526195B (en) * | 1997-06-10 | 2003-04-01 | Novartis Ag | Crystal modifications of 1-(2,6-difluorobenzyl)-1H-1,2,3-triazole-4-carboxamide and their use |
AU2003249658A1 (en) * | 2002-05-31 | 2003-12-19 | Schering Corporation | Xanthine phosphodiesterase v inhibitor polymorphs |
GB0507298D0 (en) | 2005-04-11 | 2005-05-18 | Novartis Ag | Organic compounds |
US7875284B2 (en) * | 2006-03-10 | 2011-01-25 | Cook Incorporated | Methods of manufacturing and modifying taxane coatings for implantable medical devices |
US20090069390A1 (en) * | 2007-09-12 | 2009-03-12 | Protia, Llc | Deuterium-enriched rufinamide |
JP2012505191A (en) | 2008-10-13 | 2012-03-01 | シプラ・リミテッド | Method for producing rufinamide |
CN101768124B (en) * | 2008-12-30 | 2012-01-04 | 北京本草天源药物研究院 | Medicine crystal, preparation method and purpose thereof |
IT1395736B1 (en) | 2009-08-04 | 2012-10-19 | Dipharma Francis Srl | CRYSTALLINE FORMS OF RUFINAMIDE |
EP2963023B1 (en) * | 2009-09-04 | 2018-04-18 | Tactical Therapeutics, Inc. | Process for preparing 5-amino-1, 2, 3-triazole orotate derivatives |
US8884026B2 (en) | 2010-04-30 | 2014-11-11 | Laboratorios Lesvi, S.L. | Process for preparing rufinamide intermediate |
EP2465853A1 (en) | 2010-12-14 | 2012-06-20 | Laboratorios Lesvi, S.L. | Polymorph of rufinamide and process for obtaining it |
ITMI20110718A1 (en) | 2011-04-29 | 2012-10-30 | Dipharma Francis Srl | PROCEDURE FOR PURIFICATION OF RUFINAMIDE |
WO2014013511A2 (en) * | 2012-07-20 | 2014-01-23 | Hetero Research Foundation | Rufinamide solid dispersion |
WO2021099481A1 (en) | 2019-11-20 | 2021-05-27 | Medichem, S.A. | Solid composition containing rufinamide |
Family Cites Families (23)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3992378A (en) | 1973-12-26 | 1976-11-16 | Eli Lilly And Company | Fluoralkyl quinoxadinediones |
US4156734A (en) * | 1976-02-13 | 1979-05-29 | Merck & Co., Inc. | Antihypertensive compositions containing an aryl-substituted alanine azo and an arylhydrazino-propionic acid |
GB1511195A (en) | 1976-10-18 | 1978-05-17 | Ici America Inc | Triazole derivatives |
US4536518A (en) * | 1979-11-01 | 1985-08-20 | Pfizer Inc. | Antidepressant derivatives of cis-4-phenyl-1,2,3,4-tetrahydro-1-naphthalenamine |
US4346097A (en) * | 1980-09-30 | 1982-08-24 | Warner-Lambert Company | Method for treating convulsions with pyrazole-4-carboxamide derivatives |
FI834666A (en) | 1982-12-23 | 1984-06-24 | Ciba Geigy Ag | FOERFARANDE FOER FRAMSTAELLNING AV NYA ARALKYLTRIAZOLFOERENINGAR. |
US4789680A (en) * | 1982-12-23 | 1988-12-06 | Ciba-Geigy Corporation | Aralkyltriazole compounds |
US4511572A (en) * | 1983-03-18 | 1985-04-16 | The University Of Kentucky Research Foundation | Triazoline anticonvulsant drugs |
PH22568A (en) * | 1985-04-18 | 1988-10-17 | Ciba Geigy Ag | Fluorinated benzyl triazoles and pharmaceutical compositions containing the same |
CA2002864C (en) | 1988-11-29 | 1999-11-16 | Eddy J. E. Freyne | (1h-azol-1-ylmethyl) substituted quinoline, quinazoline or quinoxaline derivatives |
JPH02214504A (en) | 1989-02-15 | 1990-08-27 | Nissan Chem Ind Ltd | Method for depositing crystal of compound having plural crystal forms |
WO1991001724A1 (en) | 1989-07-27 | 1991-02-21 | G.D. Searle & Co. | Renal-selective prodrugs for the treatment of hypertension |
IL96507A0 (en) | 1989-12-08 | 1991-08-16 | Merck & Co Inc | Nitrogen-containing spirocycles and pharmaceutical compositions containing them |
AU656154B2 (en) | 1990-11-06 | 1995-01-27 | Astellas Pharma Inc. | Fused pyrazine derivative |
JP2753911B2 (en) | 1991-12-06 | 1998-05-20 | キッセイ薬品工業株式会社 | Crystal polymorph of N-tert-butyl-1-methyl-3,3-diphenylpropylamine hydrochloride and method for producing the same |
DE4217952A1 (en) | 1992-05-30 | 1993-12-02 | Basf Ag | Quinoxaline-2,3 (1H, 4H) diones |
US5248699A (en) * | 1992-08-13 | 1993-09-28 | Pfizer Inc. | Sertraline polymorph |
US5631373A (en) | 1993-11-05 | 1997-05-20 | State Of Oregon, Acting By And Through The Oregon State Board Of Higher Education, Acting For And On Behalf Of The Oregon Health Sciences University And The University Of Oregon, Eugene Oregon | Alkyl, azido, alkoxy, and fluoro-substituted and fused quinoxalinediones |
GB9418443D0 (en) | 1994-09-13 | 1994-11-02 | Pfizer Ltd | Therapeutic agents |
GB9419318D0 (en) | 1994-09-24 | 1994-11-09 | Pfizer Ltd | Therapeutic agents |
KR100419355B1 (en) | 1995-02-22 | 2004-06-04 | 훽스트파마슈티칼스앤드케미칼스가부시키가이샤 | Amorphous piretanide, piretanide polymorphs, process for their preparation and theire use |
BR9710252B1 (en) * | 1996-07-11 | 2010-06-29 | process for preparing 4-substituted 4-cyano-1,2,3-triazoles. | |
TW526195B (en) * | 1997-06-10 | 2003-04-01 | Novartis Ag | Crystal modifications of 1-(2,6-difluorobenzyl)-1H-1,2,3-triazole-4-carboxamide and their use |
-
1998
- 1998-06-04 TW TW087108858A patent/TW526195B/en not_active IP Right Cessation
- 1998-06-04 TW TW087108859A patent/TW403740B/en not_active IP Right Cessation
- 1998-06-08 AT AT98934929T patent/ATE232852T1/en active
- 1998-06-08 AU AU84372/98A patent/AU725517B2/en not_active Expired
- 1998-06-08 IL IL12573298A patent/IL125732A/en not_active IP Right Cessation
- 1998-06-08 ES ES98934930T patent/ES2197485T3/en not_active Expired - Lifetime
- 1998-06-08 DK DK98934929T patent/DK0994863T3/en active
- 1998-06-08 CZ CZ19982534A patent/CZ292260B6/en not_active IP Right Cessation
- 1998-06-08 PL PL330764A patent/PL191943B1/en unknown
- 1998-06-08 SI SI9830450T patent/SI0994864T1/en unknown
- 1998-06-08 CN CNB2004100473675A patent/CN1298708C/en not_active Expired - Lifetime
- 1998-06-08 BR BR9804947A patent/BR9804947A/en not_active Application Discontinuation
- 1998-06-08 PE PE1998000478A patent/PE79799A1/en not_active IP Right Cessation
- 1998-06-08 JP JP53628898A patent/JP3672574B2/en not_active Expired - Lifetime
- 1998-06-08 TR TR1998/01631T patent/TR199801631T1/en unknown
- 1998-06-08 WO PCT/EP1998/003427 patent/WO1998056772A1/en active IP Right Grant
- 1998-06-08 PT PT98934930T patent/PT994864E/en unknown
- 1998-06-08 KR KR10-1998-0708149A patent/KR100409168B1/en not_active IP Right Cessation
- 1998-06-08 IL IL12573398A patent/IL125733A/en active Protection Beyond IP Right Term
- 1998-06-08 SI SI9830405T patent/SI0994863T1/en unknown
- 1998-06-08 SK SK1094-98A patent/SK283734B6/en not_active IP Right Cessation
- 1998-06-08 NZ NZ331371A patent/NZ331371A/en not_active IP Right Cessation
- 1998-06-08 CN CN988000113A patent/CN1132820C/en not_active Expired - Lifetime
- 1998-06-08 DE DE122007000051C patent/DE122007000051I2/en active Active
- 1998-06-08 HU HU0002113A patent/HU225153B1/en unknown
- 1998-06-08 TR TR1998/01630T patent/TR199801630T1/en unknown
- 1998-06-08 SK SK1093-98A patent/SK283685B6/en not_active IP Right Cessation
- 1998-06-08 DE DE69813560T patent/DE69813560T2/en not_active Expired - Lifetime
- 1998-06-08 US US09/125,329 patent/US6740669B1/en not_active Expired - Lifetime
- 1998-06-08 PE PE1998000479A patent/PE80999A1/en not_active IP Right Cessation
- 1998-06-08 EP EP98934930A patent/EP0994864B1/en not_active Expired - Lifetime
- 1998-06-08 CA CA002256015A patent/CA2256015C/en not_active Expired - Lifetime
- 1998-06-08 ID IDW980066D patent/ID21014A/en unknown
- 1998-06-08 NZ NZ331370A patent/NZ331370A/en not_active IP Right Cessation
- 1998-06-08 EP EP98934929A patent/EP0994863B1/en not_active Expired - Lifetime
- 1998-06-08 CZ CZ19982533A patent/CZ292481B6/en not_active IP Right Cessation
- 1998-06-08 DK DK98934930T patent/DK0994864T3/en active
- 1998-06-08 RU RU99104299/04A patent/RU2194041C2/en active
- 1998-06-08 ES ES98934929T patent/ES2192779T3/en not_active Expired - Lifetime
- 1998-06-08 WO PCT/EP1998/003428 patent/WO1998056773A1/en active IP Right Grant
- 1998-06-08 CA CA002256013A patent/CA2256013C/en not_active Expired - Lifetime
- 1998-06-08 JP JP53628998A patent/JP3672575B2/en not_active Expired - Lifetime
- 1998-06-08 PL PL330798A patent/PL192114B1/en unknown
- 1998-06-08 CA CA2614926A patent/CA2614926C/en not_active Expired - Lifetime
- 1998-06-08 DE DE69811500T patent/DE69811500T2/en not_active Expired - Lifetime
- 1998-06-08 RU RU99104300/04A patent/RU2198167C2/en active
- 1998-06-08 ID IDW980065D patent/ID27660A/en unknown
- 1998-06-08 AU AU84371/98A patent/AU725528B2/en not_active Expired
- 1998-06-08 KR KR10-1998-0708150A patent/KR100425656B1/en not_active IP Right Cessation
- 1998-06-08 AT AT98934930T patent/ATE237599T1/en active
- 1998-06-08 BR BR9804946A patent/BR9804946A/en not_active Application Discontinuation
- 1998-06-08 HU HU0000798A patent/HU226107B1/en unknown
- 1998-06-08 CN CNB988056755A patent/CN1159300C/en not_active Expired - Lifetime
- 1998-06-09 ZA ZA984967A patent/ZA984967B/en unknown
- 1998-06-09 CO CO98032885A patent/CO4940448A1/en unknown
- 1998-06-09 AR ARP980102708A patent/AR012946A1/en not_active Application Discontinuation
- 1998-06-09 MY MYPI98002572A patent/MY125854A/en unknown
- 1998-06-09 ZA ZA984966A patent/ZA984966B/en unknown
- 1998-06-09 CO CO98032879A patent/CO4940452A1/en unknown
- 1998-06-09 MY MYPI98002570A patent/MY120156A/en unknown
- 1998-06-09 AR ARP980102707A patent/AR012945A1/en not_active Application Discontinuation
- 1998-08-11 NO NO19983666A patent/NO329314B1/en not_active IP Right Cessation
- 1998-08-11 NO NO19983667A patent/NO329315B1/en not_active IP Right Cessation
-
1999
- 1999-12-10 UY UY25844A patent/UY25844A1/en not_active Application Discontinuation
-
2000
- 2000-10-25 HK HK00106807A patent/HK1028242A1/en not_active IP Right Cessation
- 2000-10-25 HK HK00106804A patent/HK1028241A1/en not_active IP Right Cessation
- 2000-11-17 HK HK00107340A patent/HK1028031A1/en not_active IP Right Cessation
-
2001
- 2001-05-31 US US09/871,366 patent/US6455556B2/en not_active Expired - Lifetime
-
2002
- 2002-11-14 US US10/294,408 patent/US20030125568A1/en not_active Abandoned
-
2004
- 2004-02-26 US US10/787,528 patent/US20040167186A1/en not_active Abandoned
-
2006
- 2006-01-11 US US11/329,945 patent/US7750028B2/en not_active Expired - Fee Related
-
2007
- 2007-05-17 AR ARP070102131A patent/AR061004A2/en unknown
- 2007-05-17 AR ARP070102132A patent/AR061005A2/en not_active Application Discontinuation
- 2007-07-03 NL NL300284C patent/NL300284I2/en unknown
- 2007-07-04 LU LU91345C patent/LU91345I2/en unknown
- 2007-07-06 FR FR07C0037C patent/FR07C0037I2/fr active Active
- 2007-07-13 CY CY200700014C patent/CY2007014I2/en unknown
-
2010
- 2010-04-26 US US12/767,003 patent/US8076362B2/en not_active Expired - Fee Related
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US7750028B2 (en) | Crystal modifications of 1-(2,6-difluorobenzyl)-1H-1, 2,3-triazole-4-carboxamide | |
TWI379681B (en) | Polymorphs of eltrombopag and eltrombopag salts and processes for preparation thereof | |
MXPA98006951A (en) | Crystal modification of 1-(2,6-difluorobenzyl)-1h-1,2,3--triazole-4-carboxamide and its use as antiepileptic | |
MXPA98006950A (en) | Crystal modification of 1-(2,6-difluorobenzyl)-1h-1,2,3-triazole-4-carboxamide and its use as antiepileptic |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
EEER | Examination request | ||
MKEX | Expiry |
Effective date: 20180608 |